Medical air ( DrugBank: Medical air )

---

3 diseases

ID	Disease name (Link within this page)	Number of trials
85	Idiopathic interstitial pneumonia	2
86	Pulmonary arterial hypertension	1
193	Prader-Willi syndrome	1

85. Idiopathic interstitial pneumonia

---

Clinical trials : 627 /  Drugs : 443 - (DrugBank : 120) / Drug target genes : 99 - Drug target pathways : 212

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05052229 (ClinicalTrials.gov)	April 21, 2022	2/9/2021	Inhaled Nitric Oxide (iNO) in Idiopathic Pulmonary Fibrosis (IPF).	Pulmonary Gas Exchange and Neuro-sensory Abnormalities in Patients With Idiopathic Pulmonary Fibrosis and Mild Mechanical Restriction. Implications for Dyspnea and Exercise Intolerance	Idiopathic Pulmonary Fibrosis	Drug: Nitric Oxide;Drug: Medical air	Queen's University	Boehringer Ingelheim	Recruiting	40 Years	N/A	All	40	Early Phase 1	Canada
2	NCT03688334 (ClinicalTrials.gov)	June 1, 2018	20/9/2018	Acute Effects of Oxygen Supplementation Among IPF Patients	Acute Effects of Oxygen Supplementation During Exercise Among Patients With Idiopathic Pulmonary Fibrosis Without Resting Hypoxemia	Idiopathic Pulmonary Fibrosis	Drug: Oxygen 40 %;Drug: Medical air (sham O2)	George Papanicolaou Hospital	NULL	Unknown status	18 Years	80 Years	All	15	N/A	Greece

86. Pulmonary arterial hypertension

---

Clinical trials : 1,205 /  Drugs : 684 - (DrugBank : 124) / Drug target genes : 100 - Drug target pathways : 193

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03683082 (ClinicalTrials.gov)	June 5, 2018	20/9/2018	Oxygen Treatment and Pulmonary Arterial Hypertension	Acute Effects of Oxygen Supplementation Among Pulmonary Arterial Hypertension Patients	Pulmonary Arterial Hypertension	Drug: Oxygen supplementation;Drug: Sham O2 (medical air)	George Papanicolaou Hospital	NULL	Unknown status	18 Years	80 Years	All	10	N/A	Greece

193. Prader-Willi syndrome

---

Clinical trials : 113 /  Drugs : 111 - (DrugBank : 26) / Drug target genes : 48 - Drug target pathways : 102

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03031626 (ClinicalTrials.gov)	September 1, 2016	20/1/2017	Oxygen Versus Medical Air for Treatment of CSA in Prader Will Syndrome	Comparison of Therapeutic Oxygen Versus Medical Air for the Treatment of Central Sleep Apnea in Infants and Children With Prader Willi Syndrome: A Proof of Concept Study	Sleep Apnea, Central;Prader-Willi Syndrome	Biological: Medical Air vs Oxygen	The Hospital for Sick Children	NULL	Recruiting	N/A	2 Years	All	10	Phase 4	Canada